DEA Gives CBD Derived Pharmaceutical, Epidiolex, Approval as a Schedule V Drug | CashCropToday
0 Shares 246 Views

DEA Gives CBD Derived Pharmaceutical, Epidiolex, Approval as a Schedule V Drug

September 27, 2018
246 Views

The Drug Enforcement Administration (DEA) has given the Cannabidiol (CBD) derived pharmaceutical product, Epidiolex, a reported Schedule V status. The newly approved drug is an oral solution that is used for the reduction of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

The CBD product Epidiolex is derived from the cannabis plant and will be available to patients 2 years old or older suffering from these syndromes that product seizures. Epidiolex is manufactured and produced by public company GW Pharmaceuticals (NASDAQ: GWPH) who has seen a recent spike in their stock price since the FDA had approved the products for patients in the United States earlier this year.

A Schedule V status under the DEA states, “Schedule V drugs, substances, or chemicals are defined as drugs with lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics.”

Recently, the FDA conducted a series of randomized clinical trials with patients suffering from these diseases that found that Epidiolex was successful in the reduction of seizures. Cannabidiol is non-psychoactive and can be extracted from both the cannabis and industrial hemp plants. It has shown to be effective in the reduction of anxiety, depression, inflammation, seizures, Alzheimer’s, and a number of different ailments.

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
270 views
Market Watch
270 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
194 views
Global
194 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
190 views
Manufacturing
190 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: